Abstract By 2060, the CDC projects that the Latino population will experience the largest increase in Alzheimer’s disease and related dementia (ADRD) cases of all US ethnic/racial groups. The main explanation for high Latino ADRD is attributed largely to early and excess cardiovascular disease (CVD) morbidity contributing to disparately high ADRD. CVD risk factors emerge early in midlife among Latinos, thereby increasing exposures to exquisitely sensitive and highly vascularized brain tissue. Yet, to-date there has not been any study of Latinos with sufficiently deep CVD phenotyping and genotyping to adequately address this significant public health question. This scientific knowledge gap is a significant impediment to the field and public health given rapid Latino population growth projections, particularly for older adults. The Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer’s Disease (SOL-INCA-AD) will augment the ongoing large, representative and unique cohort with 10-years of advanced biomarkers of Alzheimer's disease to understand cognitive aging and impairment amongst diverse Latinos. Together with 10-years of cognitive measures, MRI, deep CVD phenotyping, genomics and rich sociocultural data, SOL-INCA-AD is a high priority study that will fill major scientific knowledge gaps that form barriers to progress for Latino ADRD research.